Overed-Sayer et al. [78] reported that nintedanib inhibits MCs survival both in vitro and in vivo via ckit (also known as CD117 or SCF receptor); however, the efficacy of nintedanib in IPF likely resides in the drug’s ability to modulate multiple fibrotic pathways. Here, KIT is linked to idiopathic pulmonary fibrosis.